Evidence map›Paper›PMID 31564673›Full record

ReviewFukushima journal of medical science2020

Gut and oral microbiota in autoimmune liver disease.

Kazumichi Abe, Masashi Fujita, Manabu Hayashi, Ken Okai, Atsushi Takahashi, Hiromasa Ohira

Abstract readReview
In one paragraph

Review in Fukushima journal of medical science, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed.

  1. Plant-DerivedNutrients · 2022
    Trial
  2. Tongue-coating microbiome as a predictor of solid tumors: an updated scoping review of clinical studies.Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan · 2026
    Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. The oral microbiome in autoimmune diseases: friend or foe?Journal of translational medicine · 2023
    Review
  10. Review
  11. Article
  12. The Effects of Benoxacor on the Liver and Gut Microbiome of C57BL/6 Mice.Toxicological sciences : an official journal of the Society of Toxicology · 2022
    Article
  13. Review
  14. The gut-liver axis as a target of liver disease management.Hepatobiliary surgery and nutrition · 2021
    Article
  15. Review
  16. Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Kazumichi AbeDepartment of Gastroenterology, Fukushima Medical University School of Medicine.
Masashi FujitaDepartment of Gastroenterology, Fukushima Medical University School of Medicine.
Manabu HayashiDepartment of Gastroenterology, Fukushima Medical University School of Medicine.
Ken OkaiDepartment of Gastroenterology, Fukushima Medical University School of Medicine.
Atsushi TakahashiDepartment of Gastroenterology, Fukushima Medical University School of Medicine.
Hiromasa OhiraDepartment of Gastroenterology, Fukushima Medical University School of Medicine.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The gut microbiota plays a key role in the development of chronic inflammatory liver disease. The gut-liver axis involves inflammatory cells, cytokines, and other molecules that cause liver deterioration. Dysbiosis is important in understanding several liver diseases, especially in relation to the development of autoimmune liver disease. The aim of this review is to provide a current overview of alterations in the gut and oral microbiota associated with autoimmune liver diseases.

Indexed as

DysbiosisGastrointestinal MicrobiomeHepatitis, AutoimmuneHumansLiver Cirrhosis, BiliaryMouthautoimmune hepatitisgut microbiotaoral microbiotaprimary biliary cholangitis

Identifiers

PMID31564673
PMCPMC7012591

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.